Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test duo may flag High-Risk lupus kidney patients

NCT ID NCT07783711

Knowledge-focused Sponsor: Khaled Samir Malak Nashed Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 25, 2026 · Last updated Aug 27, 2026 · Updated 2 times

Summary

This study looks at whether two simple blood test ratios—neutrophil-to-lymphocyte ratio (NLR) and C-reactive protein to serum albumin ratio (CAR)—can predict which hospitalized adults with lupus nephritis will need intensive care or die during their stay. Researchers will compare these markers against standard tests to see which is more accurate. The goal is to find an easy, early warning sign for severe complications.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
No drug or treatment is being tested. The study evaluates two blood-based biomarkers: the neutrophil-to-lymphocyte ratio (NLR) and the C-reactive protein to serum albumin ratio (CAR).
What this could lead to
If these blood tests prove reliable, they could help doctors quickly identify which lupus nephritis patients are at highest risk of severe complications, potentially guiding earlier intensive care.
What could go wrong
This is a small, observational study, so the results may not apply to all patients. The biomarkers might not be strong enough predictors to change clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 55 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Hospitalized adult patients with Lupus Nephritis.

Ages

18 to 70 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years. * Diagnosis of systemic lupus erythematosus according to the 2019 EULAR/ACR Classification Criteria. * Biopsy-proven lupus nephritis or clinically diagnosed lupus nephritis according to the treating nephrologist based on clinical, laboratory and immunological findings. * Hospitalization because of active lupus nephritis or complications related to lupus nephritis. * Provision of written informed consent. Exclusion Criteria: * Age below 18 years. * Previous kidney transplantation. * Maintenance dialysis for more than three months before hospital admission. * Active malignancy. * Pregnancy. * Refusal to participate

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lupus nephritis (LN) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lupus nephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lupus nephritis (LN)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.